Biogen Signs a License Agreement with ViGeneron for Ophthalmic Gene Therapy Development

 Biogen Signs a License Agreement with ViGeneron for Ophthalmic Gene Therapy Development

Biogen Signs a License Agreement with ViGeneron for Ophthalmic Gene Therapy Development

Shots:

  • ViGeneron to receive an up front and R&D funding for the mutually agreed workplan and will receive development, regulatory and commercial milestone payments along with royalties on sales of products arising from the collaborations
  • ViGeneron will optimize and validate in vitro therapeutic candidates for undisclosed target to treat inherited eye disease while Biogen has the right to add an additional reserved target within two years after the effective date
  • The companies will work together on the in vivo POC and will use ViGeneron’s vgAAV technology to efficiently transduce target cells via intravitreal injections

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Fierce Biotech

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post